These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 840136)

  • 21. Diuretic effect and pharmacokinetic data observed at different stages of chronic renal failure with 240 mg of muzolimine.
    Baumelou A; Singlas E; Ritter W; Merdjan H; Martre H; Brouard R; Chickh-Touami C; Patte R
    Z Kardiol; 1985; 74 Suppl 2():88-91. PubMed ID: 4002810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative pharmacokinetic analysis of novel sustained-release dosage forms of pentoxifylline in healthy subjects.
    Raz I; Ben-David J; Hussein Z; Samara E
    Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):206-8. PubMed ID: 3403100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disposition kinetics of dibekacin in normal subjects and in patients with renal failure.
    Arancibia A; Chávez J; Ibarra R; Ruiz I; Icarte A; Thambo S; Chávez H
    Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):38-43. PubMed ID: 3557728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum amylase determinations and amylase to creatinine clearance ratios in patients with chronic renal insufficiency.
    Tedesco FJ; Harter HR; Alpers DH
    Gastroenterology; 1976 Oct; 71(4):594-8. PubMed ID: 955346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pentoxifylline (Trental)--a new drug for the treatment of peripheral chronic occlusive arterial disease.
    Chopra HK; Chopra KL; Aggarwal KK; Parashar SK
    J Med; 1988; 19(2):89-107. PubMed ID: 3049876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.
    Rey E; d'Athis P; Richard MO; Fillastre JP; Olive G
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):648-52. PubMed ID: 6526539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of orally administered pentoxifylline in humans.
    Smith RV; Waller ES; Doluisio JT; Bauza MT; Puri SK; Ho I; Lassman HB
    J Pharm Sci; 1986 Jan; 75(1):47-52. PubMed ID: 3958905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The excretion of pentoxifylline and its metabolites into human breast milk.
    Witter FR; Smith RV
    Am J Obstet Gynecol; 1985 Apr; 151(8):1094-7. PubMed ID: 3985069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Usefulness of pentoxifylline in the therapy of venous and mixed dystrophic ulcers of the legs].
    Galbiati G; Carnovali M
    G Ital Dermatol Venereol; 1987 Apr; 122(4):XXI-XXIV. PubMed ID: 3610219
    [No Abstract]   [Full Text] [Related]  

  • 30. Alteration of pentoxifylline pharmacokinetics by cimetidine.
    Mauro VF; Mauro LS; Hageman JH
    J Clin Pharmacol; 1988 Jul; 28(7):649-54. PubMed ID: 3216031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous determination of pentoxifylline and its hydroxy metabolite in plasma by high-performance liquid chromatography.
    Chivers DA; Birkett DJ; Miners JO
    J Chromatogr; 1981 Sep; 225(1):261-5. PubMed ID: 7298755
    [No Abstract]   [Full Text] [Related]  

  • 32. Determination of pentoxifylline and a major metabolite, 3,7-dimethyl-1-(5'-hydroxyhexyl)xanthine, by high-performance liquid chromatography.
    Luke DR; Rocci ML
    J Chromatogr; 1986 Jan; 374(1):191-5. PubMed ID: 3949928
    [No Abstract]   [Full Text] [Related]  

  • 33. Determination of pentoxifylline and its 5-hydroxy metabolite in human plasma by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection.
    Musch G; Hamoir T; Massart DL
    J Chromatogr; 1989 Oct; 495():215-26. PubMed ID: 2613806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-performance liquid chromatographic determination of pentoxifylline and its hydroxy metabolite in human plasma.
    Garnier-Moiroux A; Poirier JM; Cheymol G; Jaillon P
    J Chromatogr; 1987 Apr; 416(1):183-8. PubMed ID: 3597635
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacokinetics of pentoxifylline and its main metabolites in patients with different degrees of heart failure following a single dose of a modified-release formulation.
    Nisi A; Panfili M; De Rosa G; Boffa G; Groppa F; Gusella M; Padrini R
    J Clin Pharmacol; 2013 Jan; 53(1):51-7. PubMed ID: 23400743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacokinetics of oxpentifylline in man when administered by constant intravenous infusion.
    Ings RM; Nüdemberg F; Burrows JL; Bryce TA
    Eur J Clin Pharmacol; 1982; 23(6):539-43. PubMed ID: 7160423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The experimental and clinical studies of oxystarch in chronic renal failure (author's transl)].
    Inoshita K
    Nihon Jinzo Gakkai Shi; 1980 Mar; 22(3):315-30. PubMed ID: 7382171
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of oral or intravenous pentoxifylline on ocular and optic nerve blood flow.
    Jay WM; Aziz MZ; Chapman JM; Green K
    Ophthalmic Res; 1987; 19(6):318-21. PubMed ID: 3441353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of theophylline assay interference from pentoxifylline and its metabolites.
    Morton MR; Parish RC; Spruill WJ
    Ther Drug Monit; 1989; 11(3):347-8. PubMed ID: 2728093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood glucose and serum insulin levels following acute and chronic pentoxifylline administration.
    Heidrich H; Schirop T
    Acta Diabetol Lat; 1980; 17(1):15-21. PubMed ID: 6998241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.